Multi-Agent Treatment Offers Hope in Advanced or Recurrent Endometrial Cancer
MADRID — Immunotherapy, chemotherapy, and a PARP inhibitor in the first line improved progression-free survival (PFS) in patients with advanced or recurrent endometrial cancer, according to the DUO-E trial. The trial assessed the combination of durvalumab (Imfinzi) and platinum-based chemotherapy, followed by maintenance therapy with either durvalumab plus the PARP inhibitor olaparib (Lynparza) or durvalumab […]
Tebentafusp’s OS Benefit in Uveal Melanoma Holds Up at 3 Years
MADRID — The significant survival benefit with the bispecific T-cell receptor therapy tebentafusp (Kimmtrak) held up at 3 years for selected patients with previously untreated metastatic uveal melanoma, updated results of a phase III trial demonstrated. In HLA-A*02:01-positive patients, landmark analyses showed improved overall survival (OS) at 1, 2, and 3 years with tebentafusp versus […]
Study Validates Accuracy of PREDICT Prognostication Tool in Breast Cancer
The PREDICT prognostication tool was able to estimate overall survival (OS) with decent accuracy in a large independent U.S. dataset of breast cancer patients, researchers reported. From more than 700,000 patients in the National Cancer Database (NCDB), the free online tool estimated median and mean 5-year OS rates ranging from 83.3% to 84.4%, as compared […]
Fresh Blood Not Always the Best Blood?
Longer storage of red blood cell (RBC) units was associated with longer transplant survival in kidney transplant patients receiving early transfusions, a retrospective study in France found. Among 3,483 kidney recipients who received RBC transfusions within 14 days posttransplant, each additional day of RBC storage was associated with a non-significant 1% reduction in the risk […]
Ravulizumab Showed Preclinical Promise for ALS. What Happened?
Ravulizumab (Ultomiris), a terminal complement C5 inhibitor, did not improve functional status and survival in patients with amyotrophic lateral sclerosis (ALS), the phase III CHAMPION-ALS trial showed. No significant difference between ravulizumab and placebo emerged in Combined Assessment of Function and Survival (CAFS) scores at week 50 (mean difference of 5.5 points, 95% CI -15.7 […]
Study Reinforces BRAF-MEK Inhibition Over Anti-BRAF Only in Advanced Melanoma
Combined BRAF-MEK inhibition for advanced BRAF-mutant melanoma led to significantly better progression-free survival (PFS) as compared with single-agent BRAF inhibition, according to a randomized trial. Patients who received encorafenib (Braftovi) plus binimetinib (Mektovi) had a median PFS of 12.9 months as compared with 9.2 and 7.4 months for two cohorts treated with encorafenib alone. The […]
Adjuvant Everolimus Falls Short in High-Risk Renal Cancer
Adjuvant everolimus (Afinitor) failed to significantly improve recurrence-free survival (RFS) in patients with renal cell carcinoma (RCC) who were at high risk for recurrence after nephrectomy, according to results from a randomized phase III trial. The so-called EVEREST study showed that among 1,545 patients with histologically confirmed RCC who had undergone a full surgical resection, […]
Hemodiafiltration Reduced Dialysis Mortality in Kidney Failure
High-dose hemodiafiltration improved survival compared with standard hemodialysis for patients with kidney failure resulting in the need for kidney-replacement therapy, according to the randomized CONVINCE trial. High-dose hemodiafiltration cut all-cause mortality to 17.3% compared with 21.9% on conventional high-flux hemodialysis over a median 30 months of follow-up (HR 0.77, 95% CI 0.65-0.93), reported researchers led […]
Novel IDH1/2 Inhibitor Shows ‘Dramatic Effect’ in Low-Grade Glioma
CHICAGO — Oral vorasidenib monotherapy significantly improved progression-free survival (PFS), and delayed the time to next therapy, in patients with mutated, low-grade glioma, according to an interim analysis of the INDIGO trial. Among 331 patients with grade 2 isocitrate dehydrogenase (IDH)-mutant glioma, who received no prior treatment other than surgery, those randomly assigned to receive […]
Perioperative Toripalimab Prolongs EFS in Stage III Lung Cancer
Adding an investigational anti-PD-1 drug to perioperative chemotherapy improved event-free survival (EFS) in patients with resectable, stage III non-small cell lung cancer (NSCLC), an interim analysis of a phase III study found. Among 404 patients receiving perioperative chemotherapy in the so-called Neotorch trial, the median investigator-assessed EFS was not reached in patients assigned to toripalimab, […]